ABSTRACT
Thrombophilia by definition represents acquired and/or genetic conditions that predispose patients to both venous and arterial thromboembolic events. Thrombosis is the most common cause of death worldwide. On the arterial side, myocardial infarction and stroke result in significant morbidity and mortality. Venous thromboembolic events most commonly involve the deep veins of the lower extremity with potential complications of pulmonary emboli. Pregnancy is a hypercoagulable state, and thromboembolism is the leading cause of antepartum and postpartum maternal mortality. With the description by Dahlback in 1993 of a condition initially labeled activated protein C resistance, significant advances have rapidly followed. Activated protein C resistance was linked to an underlying point mutation resulting in coagulation factor V (factor V Leiden). Recent attention has focused on certain inherited thrombophilic factors that may predispose to arterial and/or venous thromboses and their possible association with pregnancy complications, including early pregnancy loss. These include a group of mostly autosomal dominant, inherited gene mutations leading to a hypercoagulable state, such as factor V Leiden G1691A, factor II or prothrombin G20210A, and hyperhomocysteinemia associated with methylenetetrahydrofolate reductase C677T mutation. In addition, deficiencies in protein S, protein C, and antithrombin can lead to a hypercoagulable state. Although some studies of recurrent pregnancy loss patients with a positive test for an inherited thrombophilia are conflicting, a case-control study of untreated recurrent miscarriage patients who were heterozygous for the factor V Leiden mutation revealed a lower success rate than the controls who had a history of idiopathic recurrent miscarriage. With the identification of genetic risk factors, there has been synergistic amplification of thrombotic risk when one has an abnormal gene (e.g., factor V Leiden) plus environmental issues (e.g., pregnancy). Current understanding indicates that a combination of risk factors, including multiple inherited thrombophilic defects associated with secondary hypercoagulable states, have a particularly strong association with adverse pregnancy outcome.
KEYWORDS
Recurrent pregnancy loss - thrombophilias - coagulation abnormalities - miscarriage - antiphospholipid antibodies
REFERENCES
1
Egeberg O.
Inherited antithrombin deficiency causing thrombophilia.
Thromb Diath Haemorrh.
1965;
13
516-530
2
Griffin J H, Evatt B, Zimmerman T S et al..
Deficiency of protein C in congenital thrombotic disease.
J Clin Invest.
1981;
68
1370-1373
3
Comp P C, Nixon R R, Cooper D W et al..
Familial protein S deficiency is associated with recurrent thrombosis.
J Clin Invest.
1984;
74
2082-2088
4
Dahlback B, Carlsson M, Svensson P J.
Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.
Proc Natl Acad Sci USA.
1993;
90
1004-1008
5
Bertina R M, Koeleman B PC, Koster T et al..
Mutation in blood coagulation factor V associated with resistance to activated protein C.
Nature.
1994;
369
64-66
6 Schafer A I. The primary and secondary hypercoagulable states . In: Schafer AI Molecular Mechanisms of Hypercoagulable States. New York; Chapman and Hall 1997
7
Rosendaal F R.
Risk factors for venous thrombosis: prevalence, risk, and interaction.
Semin Hematol.
1997;
34
171-187
8 Goodnight S H, Hathaway W E. Disorders of Hemostasis and Thrombosis: A Clinical Guide. 2nd ed. New York; McGraw-Hill 2001
9 Laros R K. Thromboembolic disease . In: Creasy RK, Resnik R Maternal-Fetal Medicine. 4th ed. Philadelphia, PA; WB Saunders 1999: 821-831
10
Rai R, Regan L.
Thrombophilia and adverse pregnancy outcome.
Semin Reprod Med.
2000;
18
369-377
11
Carp H, Dolitsky M, Tur-Kaspa I, Inbal A.
Hereditary thrombophilias are not associated with a decreased live birth rate in women with recurrent miscarriage.
Fertil Steril.
2002;
78
58-62
12
Lockwood C.
Inherited thrombophilias in pregnant patients: detection and treatment paradigm.
Obstet Gynecol.
2002;
99
333-341
13
Rey E, Kahn S R, David M, Shrier I.
Thrombophilic disorders and fetal loss: a meta-analysis.
Lancet.
2003;
361
901-908
14
Kovalevsky G, Gracia C R, Berlin J A, Sammel M D, Barnhart K T.
Evaluation of the association between hereditary thrombophilias and recurrent pregnancy loss: a meta-analysis.
Arch Intern Med.
2004;
164(5)
558-563
15
Krabbendam I, Francks A, Bots M L, Fijnheer R, Bruinse H W.
Thrombophilias and recurrent pregnancy loss: a critical appraisal of the literature.
Eur J Obstet Gynecol Reprod Biol.
2005;
118
143-153
16
Thaler E, Lechner K.
Antithrombin III deficiency and thromboembolism.
Clin Haematol.
1981;
10
369-390
17
Arkel Y S, Ku D H.
Thrombophilia and pregnancy: review of the literature and some original data.
Clin Appl Thromb Hematol.
2001;
7
259-268
18
Regan L, Rai R.
Thrombophilia and pregnancy loss.
J Reprod Immunol.
2002;
55(1-2)
163-180
19
Pabinger I, Brucker S, Kyrle P A et al..
Hereditary deficiency of antithrombin III, protein C and protein S: prevalence in patients with a history of venouw thrombosis and criteria for rational patient screening.
Blood Coagul Fibrinolysis.
1992;
3
547-553
20
Dahlback B, Hildebrand B.
Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V.
Proc Natl Acad Sci.
1994;
91
1396-1400
21
Preston F E, Rosendaal F R, Walker I D et al..
Increased fetal loss in women with heritable thrombophilia.
Lancet.
1996;
348
913-916
22
Sarig G, Younis J S, Hoffman R, Lanir N, Blumenfeld Z, Brenner B.
Thrombophilia is common in women with idiopathic pregnancy loss and is associated with late pregnancy wastage.
Fertil Steril.
2002;
77
342-347
23
Rai R, Backos M, Elgaddal S, Shebak A, Regan L.
Factor V Leiden and recurrent miscarriage-prospective outcome of untreated pregnancies.
Hum Reprod.
2002;
17
442-445
24
Meinardi J R, Middeldorp S, de Kam P J et al..
Increased risk for fetal loss in carriers of the factor V Leiden mutation.
Ann Intern Med.
1999;
130
736-739
25
Poort S R, Rosendaal F R, Reitsma P H et al..
A common genetic variation in the 3′ untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis.
Blood.
1996;
88
3698-3703
26
Pihusch R, Buchholz T, Lohse P et al..
Thrombophilic gene mutations and recurrent spontaneous abortion: prothrombin mutation increases the risk in the first trimester.
Am J Reprod Immunol.
2001;
46
124-131
27
Mahjoub T, Mtiraoui N, Tamim H et al..
Association between adverse pregnancy outcomes and maternal factor V G1691A (Leiden) and prothrombin G20210A genotypes in women with a history of recurrent idiopathic miscarriages.
Am J Hematol.
2005;
80
12-19
28
McCully K S.
Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis.
Am J Pathol.
1969;
56
111-128
29
Welch G N, Loscalzo J.
Homocysteine and atherothrombosis.
N Engl J Med.
1998;
338
1042-1050
30
Frost P, Blom H J, Milos R et al..
MR: a candidate genetic risk factor for vascular disease: a common mutation in the methylene tetrahydrofolate reductase.
Nat Genet.
1995;
10
111-113
31
Jacques P, Bostom A, Williams R.
Relation between folate status a common mutation in the methlenetetrahydofolate reductase and plasma homocysteine concentrations.
Circulation.
1996;
93
7-9
32
Van der Put N MJ, Gabreels F, Stevens E MB et al..
A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural tube defects?.
Am J Hum Genet.
1998;
62
1044-1051
33
Welch G, Loscalzo J.
Homocysteine and atherothrombosis.
N Engl J Med.
1998;
338
1042-1051
34
Bonnette R E, Caudill M A, Boddie A M, Hutson A D, Kauwell G P, Bailey L B.
Plasma homocysteine concentrations in pregnant and non-pregnant women with controlled folate intake.
Obstet Gynecol.
1998;
92
167-170
35
Verhoef P, Stampfer M J, Buring J E et al..
Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B6, B12, and folate.
Am J Epidemiol.
1995;
143
845-859
36
Nelen W L, Bulten J, Steegers E A, Blom H J, Hanselaar A G, Eskes T K.
Maternal homocysteine and chorionic vascularization in recurrent early pregnancy loss.
Hum Reprod.
2000;
15
954-960
37
Nelen W L, Blom H J, Steegers E A, den Heijer M, Eskes T K.
Hyperhomocysteinemia and recurrent early pregnancy loss: a meta-analysis.
Fertil Steril.
2000;
74
1196-1199
38
Tait R, Walker I D, Perry D J et al..
Prevalence of antithrombin deficiency in the healthy population.
Br J Haematol.
1994;
87
106-112
39
Adelberg A M, Kuller J A.
Thrombophilias and recurrent miscarriage.
Obstet Gynecol Surv.
2002;
57
703-709
40
Miletich J, Sherman L, Broze G.
Absence of thrombosis in subjects with heterozygous protein C deficiency.
N Engl J Med.
1987;
317
991-996
41
Coumans A B, Huijgens P C, Jakobs C et al..
Haemostatic and metabolic abnormalities in women with unexplained recurrent abortion.
Hum Reprod.
1999;
14
211-214
42
Brandt J T, Triplett D A, Alving B, Scharrer I.
Criteria for the diagnosis of lupus anticoagulants: an update.
Thromb Haemost.
1995;
74
1185-1190
43
Wilson W A, Gharavi A E.
Koike Kea: International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop.
Arthritis Rheum.
1999;
42
1309-1311
44
Out H J, Bruinse H W, Christians C ML et al..
A prospective, controlled multicenter study of the obstetric risk Am of pregnant women with antiphospholipid antibodies.
Am J Obstet Gynecol.
1992;
167
26-32
45
Kutteh W H.
Antiphospholipid antibodies in reproduction.
J Reprod Immunol.
1997;
35
151-171
46
Esplin M S.
Antiphospholipid sundrome. ACOG Practice Bulletin No. 68.
Obstet Gynecol.
2005;
106
1113-1121
47
Rand J H.
The antiphospholipid syndrome.
Annu Rev Med.
2003;
54
409-424
48
Rand J H, Wu X X, Guller S et al..
Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion.
Am J Obstet Gynecol.
1994;
171
1566-1572
49
Shibata S, Harpel P C, Gharavi A, Rand J, Fillit H.
Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes.
Blood.
1994;
83
2532-2540
50
Ermel L D, Marshburn P B, Kutteh W H.
Interaction of heparin with antiphospholipid antibodies (APA) from the sera of women with recurrent pregnancy loss (RPL).
Am J Reprod Immunol.
1995;
33
14-20
51
Franklin R D, Kutteh W H.
Effects of unfractionated and low molecular weight heparin on antiphospholipid antibody binding in vitro.
Obstet Gynecol.
2003;
101
455-462
52
Di Simone N, Ferrazani S, Castellani R, Ce Carolis S, Mancuso S, Caruso A.
Heparin and low-dose aspirin restore placental human chorionic gonadotropin secretion abolished by antiphospholipid antibody containing sera.
Hum Reprod.
1997;
12
2061-2065
53
Girardi G.
Heparin treatment in pregnancy loss: potential therapeutic benefits beyond anticoagulation.
J Reprod Immunol.
2005;
66
45-51
54
Sarig G, Lanir N, Hoffman R, Brenner B.
Protein C global assay in the evaluation of women with idiopathic pregnancy loss.
Thromb Haemost.
2002;
88
32-36
55
Rai R, Tuddenham E, Backos M et al..
Thromboelastography, whole-blood haemostasis and recurrent miscarriage.
Hum Reprod.
2003;
18
2540-2543
56
Porter T F, Scott J R.
Evidence-based care of recurrent miscarriage.
Best Pract Res Clin Obstet Gynaecol.
2005;
19
85-101
57
Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis J S.
Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin.
Thromb Haemost.
2000;
83
693-697
58
Kutteh W H, Ermel L.
A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss lwith lower dose heparin and aspirin.
Am J Reprod Immunol.
1996;
35
402-407
59
Franklin R D, Kutteh W H.
Antiphospholipid antibodies (APA) and recurrent pregnancy loss: treating a unique APA positive population.
Hum Reprod.
2002;
17
2981-2985
60
Kutteh W H.
Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone.
Am J Obstet Gynecol.
1996;
174
1584-1589
61
Quere I, Mercier E, Bellet H, Janbon C, Mares P, Gris J C.
Vitamin supplementation and pregnancy outcome in women with recurrent early pregnancy loss and hyperhomocysteinemia.
Fertil Steril.
2001;
75
823-825
62
Pattison N S, Chamley L W, Birdsall M, Zanderigo A M, Liddell H S, McDougall J.
Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial.
Am J Obstet Gynecol.
2000;
183
1008-1012
63
Empson M, Lassere M, Craig J C, Scott J R.
Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials.
Obstet Gynecol.
2002;
99
135-144
64
Noble L S, Kutteh W H, Lashley N, Franklin R D, Herrada J.
Antiphospholipid antibodies (APA) associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with enoxaparin versus unfractionated heparin.
Fertil Steril.
2005;
83
684-690
65
Stephenson M D, Ballem P J, Tsang P et al..
Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin.
J Obstet Gynaecol Can.
2004;
26
729-734
66 Silver R M, Branch D W. Immunologic Disorders. Philadelphia, PA; WB Saunders 1999
67
Triplett D A.
Antiphospholipid protein antibodies: laboratory detection and clinical relevance.
Thromb Res.
1995;
78
1-31
68
Weiss E J, Bray P F, Tayback M et al..
A polymorphism of a platelet glycoprotein receptor as an inherited risk factor of coronary thrombosis.
N Engl J Med.
1996;
334
1090-1094
69
Vandenbrouke J P, Koster T, Briet E et al..
Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation.
Lancet.
1994;
344
1453-1457
70
Vad S, Lakos G, Kiss E, Sipka S, Csorba R, Poka R.
Antiphospholipid antibodies in young women with and without oral contraceptive use.
Blood Coagul Fibrinolysis.
2003;
14
57-60
William H KuttehM.D. Ph.D. H.C.L.D.
Professor of Obstetrics and Gynecology, Director of Reproductive Endocrinology and Infertility, Director of Reproductive Immunology, University of Tennessee, Memphis
80 Humphreys Center, Suite 307, Memphis, TN 38120-2363
Email: wkutteh@utmem.edu